Everything below concerns DPP-4 resistance. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
===== MeSH D08.811.682.660 – oxidoreductases acting on ch-ch group donors ===== MeSH D08.811.682.660.150 – acyl-coa dehydrogenases MeSH D08.811.682.660.150.100 – acyl-coa dehydrogenase MeSH D08.811.682.660.150.150 – acyl-coa dehydrogenase, long-chain MeSH D08.811.682.660.150.200 – acyl-CoA oxidase MeSH D08.811.682.660.150.300 – butyryl-coa dehydrogenase MeSH D08.811.682.660.200 – cholestenone 5alpha-reductase MeSH D08.811.682.660.250 – coproporphyrinogen oxidase MeSH D08.811.682.660.275 – dihydrodipicolinate reductase MeSH D08.811.682.660.300 – dihydroorotate oxidase MeSH D08.811.682.660.325 – dihydrouracil dehydrogenase (nad+) MeSH D08.811.682.660.350 – dihydrouracil dehydrogenase (nadp) MeSH D08.811.682.660.385 – electron transport complex ii MeSH D08.811.682.660.385.500 – succinate dehydrogenase MeSH D08.811.682.660.387 – enoyl-(acyl-carrier-protein) reductase (nadh) MeSH D08.811.682.660.390 – enoyl-(acyl-carrier protein) reductase (nadph, b-specific) MeSH D08.811.682.660.425 – Glutaryl-CoA dehydrogenase MeSH D08.811.682.660.462 – isovaleryl-coa dehydrogenase MeSH D08.811.682.660.490 – 15-oxoprostaglandin 13-reductase MeSH D08.811.682.660.500 – prephenate dehydrogenase MeSH D08.811.682.660.600 – protoporphyrinogen oxidase MeSH D08.811.682.660.750 – succinate dehydrogenase MeSH D08.811.682.660.900 – testosterone 5-alpha-Reductase
Castor oil was the preferred lubricant for rotary engines, such as the Gnome engine after that engine's widespread adoption for aviation in Europe in 1909. It was used almost universally in rotary-engined Allied aircraft in World War I. Germany had to make do with inferior ersatz oil for its rotary engines, which resulted in poor reliability. The methanol-fueled, two-cycle, glow-plug engines used for aeromodelling, since their adoption by model airplane hobbyists in the 1940s, have used varying percentages of castor oil as lubricants. It is highly resistant to degradation when the engine has its fuel-air mixture leaned for maximum engine speed. Gummy residues can still be a problem for aeromodelling powerplants lubricated with castor oil, however, usually requiring eventual replacement of ball bearings when the residue accumulates within the engine's bearing races. One British manufacturer of sleeve valved four-cycle model engines has stated the "varnish" created by using castor oil in small percentages can improve the pneumatic seal of the sleeve valve, improving such an engine's performance over time. Castor oil is still occasionally used by aeromodellers in custom fuel mixtures for methanol-burning model engines, due to Castor oil's miscibility in methanol. Typical petroleum-derived two-stroke oils designed for gasoline engines are immiscible in methanol. Castor oil is a readily available alternative to PAG (Polyalkylene Glycol) or other specialty oils for mixing affordable glow fuel (commonly referred to as "nitro fuel" by aeromodelling hobbyists).
== Habitat degradation == Human activities such as urban development, agriculture, and dam construction lead to habitat degradation, posing significant threats to aquatic plants. Urbanization increases impervious surfaces, leading to higher runoff volumes that carry pollutants and sediments into water bodies. This runoff can smother aquatic plants and alter water chemistry. Agricultural practices contribute to nutrient loading and pesticide contamination, further stressing aquatic vegetation. Dam construction and water diversion projects alter natural flow regimes, affecting sediment transport and water temperature. These changes can disrupt the life cycles of aquatic plants and the species that depend on them. Aquatic plants are integral to healthy aquatic ecosystems, but they face numerous threats from invasive species, nutrient pollution, climate change, and habitat degradation. Addressing these challenges requires integrated management approaches, including controlling invasive species, reducing nutrient inputs, mitigating climate change impacts, and protecting and restoring aquatic habitats.
cadherin Any of a class of transmembrane proteins which are dependent on calcium ions (Ca2+) and whose extracellular domains function as mediators of cell–cell adhesion at adherens junctions in eukaryotic tissues.
In the United States, the New Deal liberalism of President Franklin D. Roosevelt won mass support leaving socialists unable to gain significant ground. Norman Thomas of the Socialist Party of America (SPA) attracted nearly 188,000 votes in his 1936 run for president, but performed poorly in historic strongholds of the party and the Socialist Party of America's membership had begun to decline. Meanwhile, the Trotskyist movement, followed a policy known as the French Turn, a strategy of entryism in democratic socialist parties such as the SPA, SFIO and ILP, pulling these to the left in some places. However, fascism was also advancing. In Germany, it was the fascists of Adolf Hitler's Nazi Party who successfully exploited the Depression to win power, in January 1933. Hitler's regime swiftly destroyed both the German Communist Party and the Social Democratic Party, the worst blow the world socialist movement had ever suffered. This forced Stalin to reassess his strategy, and after its 7th World Congress in 1935 the Comintern began urging a popular front against fascism. The socialist parties were at first suspicious, given the bitter hostility of the 1920s, but eventually effective Popular Fronts were formed in both France and Spain. In Italy, the Italian Socialist Party (PSI) established an alliance with the Communists and it gradually cooperated with conservative reformists, revolutionaries, and syndicalists. In France, the Popular Front, headed by the SFIO's Léon Blum, won the 3 May 1936 election, leading to a government composed of Radical and Socialist ministers.
Sources: en.wikipedia.org
== Clinical Practice & Patient Care == AMP publishes evidence-based guidelines and freely available reports to provide best practices and recommendations, and to highlight the developments and changing practices in its rapidly evolving field. AMP frequently collaborates with other well-respected professional organizations, such as the College of American Pathologists (CAP), American Society of Clinical Oncology (ASCO), American College of Obstetricians and Gynecologists (ACOG) and American College of Medical Genetics and Genomics (ACMG) to share expertise and broaden the reach of various publications. Guidelines are authored by AMP members elected to the Clinical Practice Committee or appointed by the Board of Directors as subject matter experts to specific working groups.
Many researchers proposed that at the physiological pH, GHK-Cu complexes can form binary and ternary structures which may involve amino acid histidine and/or the copper binding region of the albumin molecule. Lau and Sarkar found also that GHK can easily obtain copper 2+ bound to other molecules such as the high affinity copper transport site on plasma albumin (albumin binding constant log 10 =16.2 vs. GHK binding constant 16 log 10 =16.44). It has been established that copper (II) redox activity is silenced when copper ions are complexed with the GHK tripeptide, which allows the delivery of non-toxic copper into the cell.
Oxazepam is an intermediate-acting benzodiazepine of the 3-hydroxy family; it acts on benzodiazepine receptors, resulting in increased effect of GABA to the GABAA receptor which results in inhibitory effects on the central nervous system. The half-life of oxazepam is between 6 and 9 hours. It has been shown to suppress cortisol levels. Oxazepam is the most slowly absorbed and has the slowest onset of action of all the common benzodiazepines according to one British study. Oxazepam is an active metabolite formed during the breakdown of diazepam, nordazepam, and certain similar drugs. It may be safer than many other benzodiazepines in patients with impaired liver function because it does not require hepatic oxidation, but rather, it is simply metabolized by glucuronidation, so oxazepam is less likely to accumulate and cause adverse reactions in the elderly or people with liver disease. Oxazepam is similar to lorazepam in this respect. Preferential storage of oxazepam occurs in some organs, including the heart of the neonate. Absorption by any administered route and the risk of accumulation is significantly increased in the neonate, and withdrawal of oxazepam during pregnancy and breast feeding is recommended, as oxazepam is excreted in breast milk. Two milligrams of oxazepam equates to 1 mg of diazepam according to the benzodiazepine equivalency converter, therefore 20 mg of oxazepam according to BZD equivalency equates to 10 mg of diazepam and 15 mg oxazepam to 7.5 mg diazepam (rounded up to 8 mg of diazepam).
Durability of the effect of mitomycin gel in subjects with a complete response was also evaluated using urine cytology, ureteroscopy and biopsy (if warranted) every three months for a year following the initiation of therapy. Nineteen subjects (46%) who achieved a complete response continued to have a complete response at the twelve-month mark. The US Food and Drug Administration (FDA) granted the application for mitomycin gel priority review along with breakthrough therapy, fast track, and orphan drug designations. The FDA granted approval of Jelmyto to UroGen Pharma, Inc. The efficacy of mitomycin C for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer was evaluated in ENVISION (NCT05243550), a single-arm, multi-center trial in 240 adults with low-grade non-muscle invasive bladder cancer that recurred after prior transurethral resection of bladder tumor and met 1-2 of the following criteria: multiple tumors, a solitary tumor >3 cm, and/or recurrence within one year. Participants received 75 mg mitomycin intravesical solution instilled once a week for six consecutive weeks. Assessment of tumor status was performed every three months by cystoscopy, for-cause biopsy, and urine cytology.
Charcuterie – the branch of cooking devoted to prepared meat products, such as bacon, ham, sausage, terrines, galantines, pâtés, and confit, primarily from pork. Charcuterie is part of the garde manger chef's repertoire. Originally intended as a way to preserve meat before the advent of refrigeration, they are prepared today for their flavors derived from the preservation processes. Charque – a form of jerky common in South America made from dried and salted meat, originally llama where this animal roamed, but nowadays mostly beef. Chinese sausage – a generic term referring to the many different types of sausages originating in China. Chipped beef – thinly sliced or pressed salted and dried beef. Some varieties are smoked to add flavor. Chorizo – can be a fresh sausage, in which case it must be cooked before eating. In Europe, it is more frequently a fermented, salt-cured, smoked sausage Cold cut – precooked or cured meat, including dried sausages. Country ham – a variety of cured ham that is typically very salty. Country hams are salt-cured (and occasionally nitrite- and nitrate-cured) for one to three months. Culatello – a refined variety of prosciutto, made from heavier pigs, cut to a fraction of the normal prosciutto and aged, and may be cured with wine, with culatello di Zibello having PDO status.
Sources: en.wikipedia.org
Ultraviolet helps detect organic material deposits that remain on surfaces where periodic cleaning and sanitizing may have failed. It is used in the hotel industry, manufacturing, and other industries where levels of cleanliness or contamination are inspected. Perennial news features for many television news organizations involve an investigative reporter using a similar device to reveal unsanitary conditions in hotels, public toilets, hand rails, and such.
The authors of one of these studies speculated that oxytocin's effects on muscle contractibility may facilitate sperm and egg transport. In a study measuring oxytocin serum levels in women before and after sexual stimulation, the author suggests it serves an important role in sexual arousal. This study found that genital tract stimulation resulted in increased oxytocin immediately after orgasm. Another study reported increases of oxytocin during sexual arousal could be in response to nipple/areola, genital, and/or genital tract stimulation as confirmed in other mammals. Murphy et al. (1987), studying men, found that plasma oxytocin levels remain unchanged during sexual arousal, but that levels increase sharply after ejaculation, returning to baseline levels within 30 minutes. In contrast, vasopressin was increased during arousal but returned to baseline at the time of ejaculation. The study concludes that (in males) vasopressin is secreted during arousal, while oxytocin is only secreted after ejaculation. A more recent study of men found an increase in plasma oxytocin immediately after orgasm, but only in a portion of their sample that did not reach statistical significance. The authors noted these changes "may simply reflect contractile properties on reproductive tissue". Due to its similarity to vasopressin, it can reduce the excretion of urine slightly, and so it can be classified as an antidiuretic. In several species, oxytocin can stimulate sodium excretion from the kidneys (natriuresis), and in humans high doses can result in low sodium levels (hyponatremia).
=== Topical === Throughout clinical trials, data from a limited number of exposed pregnancies indicate that there is no clinical evidence that treatment with eflornithine adversely affects pregnant women or fetuses.
=== Dihydrolipoyl dehydrogenase Binding protein (E3BP) === An auxiliary protein unique to most eukaryotes is the E3 binding protein (E3BP), which serves to bind the E3 subunit to the PDC complex. In the case of human E3BP, hydrophobic proline and leucine residues in the BP interact with the surface recognition site formed by the binding of two identical E3 monomers.
In addition, proteins released from cells can impede protein C activation, for example eosinophil, which may explain thrombosis in hypereosinophilic heart disease. Protein C may be up-regulated by platelet factor 4. This cytokine is conjectured to improve activation of protein C by forming an electrostatic bridge from protein C's Gla domain to the glycosaminoglycan (GAG) domain of thrombomodulin, reducing the Michaelis constant (KM) for their reaction. In addition, Protein C is inhibited by protein C inhibitor.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.